| Code | CSB-RA017647MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tafolecimab, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, promoting their lysosomal degradation. By reducing LDLR availability, elevated PCSK9 levels lead to decreased clearance of LDL cholesterol from circulation, contributing to hypercholesterolemia and increased cardiovascular disease risk. Genetic variants affecting PCSK9 function have been strongly associated with variations in plasma LDL-C levels and coronary artery disease susceptibility.
Tafolecimab represents a next-generation PCSK9 inhibitor designed for extended dosing intervals in lipid management research. This biosimilar antibody provides researchers with a cost-effective tool for investigating PCSK9 biology, lipid metabolism pathways, and atherosclerosis mechanisms. It enables studies examining PCSK9-LDLR interactions, hepatic cholesterol regulation, and potential therapeutic interventions for dyslipidemia. The antibody supports diverse experimental models exploring cardiovascular disease pathogenesis and lipid-lowering strategies.
There are currently no reviews for this product.